Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Oncology|June 7, 2017
APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cellsJing Wang, Dajun Yang, Qiuyun Luo, et al.
NPJ Precision Oncology|May 21, 2026
Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinomaZengfei Xia, Runduan Lin, Fan Luo, et al.
Biochemical Pharmacology|April 22, 2018
A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunityWentao Pan, Qiuyun Luo, Xianglei Yan, et al.
Oncology Research|February 26, 2020
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell LymphomaQiuyun Luo, Wentao Pan, Suna Zhou, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 3, 2018
A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinomaHanjie Yi, Xianglei Yan, Qiuyun Luo, et al.
International Journal of Oncology|December 8, 2023
The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastomaMengzhen Li, Yang Hu, Juan Wang, et al.
Cancer Cell International|May 24, 2024
Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cellsWentao Pan, Qiuyun Luo, Eric Liang, et al.
Oncotarget|May 13, 2017
Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cellsHaibo Chen, Dingyuan Luo, Lin Zhang, et al.
Cellular & Molecular Immunology|December 7, 2023
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activationFan Luo, Han Li, Wenjuan Ma, et al.
Pageof 2